Emergence of invasive cerebral aspergillosis in an HIV-positive patient on voriconazole therapy

HIV Medicine

Volumn 6, Issue 1, 2005, Pages 45-46

  van Hal, S J ^a   Clezy, Kate ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Cerebral aspergillosis; Immune restoration disease; Variconazole

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B LIPID COMPLEX; ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; CASPOFUNGIN; CD4 ANTIGEN; COTRIMOXAZOLE; FLUCONAZOLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PREDNISONE; STAVUDINE; VALACICLOVIR; VIRUS RNA; VORICONAZOLE;

ADULT; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BRAIN BIOPSY; BRAIN INFECTION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DETERIORATION; FEVER; FUNGUS CULTURE; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RECURRENT DISEASE; SEIZURE; THORAX RADIOGRAPHY; TOXOPLASMA GONDII; TREATMENT OUTCOME; TREATMENT REFUSAL; VARICELLA ZOSTER VIRUS; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPERGILLOSIS; FATAL OUTCOME; HUMANS; MALE; PYRIMIDINES; TRIAZOLES;

EID: 13944263300     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00256.x     Document Type: Article

References (14)

1. Klapholz A, Salmon N, Perlman DC, Talavera W. Aspergillosis in the acquired immunodeficiency syndrome. Chest 1991; 100: 1614-1618.
2. Denning DW. Invasive aspergillosis in immunocompromised patients. Curr Opin Infect Dis 1994; 7: 456-462.
3. Mylonakis E, Paliou M, Sax PE, Skolnik PR, Baron MJ, Rich JD. Central nervous system aspergillosis in patients with human immunodeficiency virus infection. Report of 6 cases and review. Medicine 2000; 79: 269-280.
4. Lin S-J, Schranz J, Teutsh SM. Aspergillosis case-fatality rate. Systematic review of the literature. Clin Infect Dis 2001; 32: 358-366.
5. Haran RP, Chandy MJ. Intracranial aspergillus granuloma. Br J Neurosurg 1993; 7: 383-388.
6. Khoo SH, Denning DW. Invasive aspergillosis in patients with AIDS. Clin Infect Dis 1994; 19 (Suppl. 1): S41-S48.
7. Herbrecht R, Denning DW, Patterson TF et al. and the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
8. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445-1457.
9. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46: 245-247.
10. Ellis M, Watson R, McNabb A, Lukic ML, Nork M. Massive intracerebral aspergillosis responding to combination high dose liposomal amphotericin B and cytokine therapy without surgery. J Med Microbiol 2002; 51: 70-75.
11. Roilides E, Lamaignere CG, Farmaki E. Cytokines in immunodeficient patients with invasive fungal infections: an emerging therapy. Int J Infect Dis 2002; 6: 154-163.
12. Kim Y, Lee KS, Jung KL et al. Halo sign on high resolution CT: findings in spectrum pulmonary disease with pathological correlation. J Comput Assist Tomogr 1999; 23: 622-626.
13. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003; 37: 728-731.
14. French MA, Lenzo N, John M et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1: 107-115.